Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate MBX Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding MBX Biosciences, Inc.’s stock price such as:

• MBX Biosciences, Inc.’s current stock price and volume
• Why MBX Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for MBX from analysts
• MBX’s stock price momentum as measured by its relative strength

About MBX Biosciences, Inc. (MBX)

Before we jump into MBX Biosciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Want to learn more about MBX Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about MBX Biosciences, Inc..

MBX Biosciences, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, MBX Biosciences, Inc.’s stock price was $65.930.

MBX Biosciences, Inc. is down 0.8% from its previous closing price of $66.460.

During the last market session, MBX Biosciences, Inc.’s stock traded between $64.500 and $69.400. Currently, there are approximately 46.58 million shares outstanding for MBX Biosciences, Inc..

MBX Biosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

MBX Biosciences, Inc. Stock Price History

MBX Biosciences, Inc.’s (MBX) price is currently up 19.44% so far this month.

During the month of July, MBX Biosciences, Inc.’s stock price has reached a high of $69.400 and a low of $52.510.

Over the last year, MBX Biosciences, Inc. has hit prices as high as $69.400 and as low as $9.630. Year to date, MBX Biosciences, Inc.’s stock is up 109.04%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused MBX Biosciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded MBX Biosciences, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate MBX Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on MBX Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about MBX Biosciences, Inc. (MBX) by visiting AAII Stock Evaluator.

Relative Price Strength of MBX Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, MBX Biosciences, Inc. has a weighted four-quarter relative price strength of 65.57%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how MBX Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

MBX Biosciences, Inc. Stock Price: Bottom Line

As of July 31, 2026, MBX Biosciences, Inc.’s stock price is $65.930, which is down 0.8% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like MBX Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.